Close

Kadmon (KDMN) Announces Updated Positive Phase 2 Data on KD025 in cGVHD

December 11, 2017 5:51 AM EST Send to a Friend
Kadmon Holdings, Inc. (NYSE: KDMN) today announced additional positive findings from an ongoing Phase 2 clinical trial demonstrating that KD025 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login